DOP2012000164A - Polipeptido de fusion contra tumor inducido por virus eb y mutante de colicina ia - Google Patents
Polipeptido de fusion contra tumor inducido por virus eb y mutante de colicina iaInfo
- Publication number
- DOP2012000164A DOP2012000164A DO2012000164A DO2012000164A DOP2012000164A DO P2012000164 A DOP2012000164 A DO P2012000164A DO 2012000164 A DO2012000164 A DO 2012000164A DO 2012000164 A DO2012000164 A DO 2012000164A DO P2012000164 A DOP2012000164 A DO P2012000164A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- mutant
- virus
- polypeptide
- colicina
- provides
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 230000004927 fusion Effects 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 108010073254 Colicins Proteins 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102200051800 rs121434525 Human genes 0.000 abstract 1
- 102200142793 rs35418374 Human genes 0.000 abstract 1
- 102220059797 rs786203763 Human genes 0.000 abstract 1
- 108700026220 vif Genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona un polipéptido de fusión contra tumor inducido por virus EB, que comprende un anticuerpo o un anticuerpo mimético contra el virus EB y una colicina que forma canales iónicos seleccionada de E1, la, lb, A, B, N y sus mutantes. La presente invención también proporciona un mutante de colicina la, que comprende mutaciones de G11A, H22G, A26G, V31L y H4OD. La presente invención también proporciona un gen, un vector, un método de preparación y el uso del polipéptido de fusión, y proporciona un gen y el uso del mutante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102428380A CN102101888B (zh) | 2009-12-17 | 2009-12-17 | 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2012000164A true DOP2012000164A (es) | 2012-12-31 |
Family
ID=44154977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2012000164A DOP2012000164A (es) | 2009-12-17 | 2012-06-13 | Polipeptido de fusion contra tumor inducido por virus eb y mutante de colicina ia |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8883161B2 (es) |
| EP (1) | EP2514768B1 (es) |
| JP (1) | JP5683603B2 (es) |
| KR (1) | KR101464842B1 (es) |
| CN (1) | CN102101888B (es) |
| AP (1) | AP3535A (es) |
| AU (1) | AU2010333588B2 (es) |
| BR (1) | BR112012017350A2 (es) |
| CA (1) | CA2784784C (es) |
| CL (1) | CL2012001609A1 (es) |
| CO (1) | CO6541633A2 (es) |
| CR (1) | CR20120329A (es) |
| CU (1) | CU20120096A7 (es) |
| DK (1) | DK2514768T3 (es) |
| DO (1) | DOP2012000164A (es) |
| EA (1) | EA030638B1 (es) |
| ES (1) | ES2634944T3 (es) |
| GE (1) | GEP20156228B (es) |
| HK (1) | HK1159123A1 (es) |
| HU (1) | HUE033298T2 (es) |
| IL (1) | IL220296A (es) |
| MA (1) | MA33921B1 (es) |
| MX (1) | MX2012006952A (es) |
| NZ (1) | NZ600729A (es) |
| PE (1) | PE20121722A1 (es) |
| SG (1) | SG181553A1 (es) |
| TN (1) | TN2012000253A1 (es) |
| UA (1) | UA104933C2 (es) |
| WO (1) | WO2011072501A1 (es) |
| ZA (1) | ZA201205217B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200251B1 (en) | 2011-03-31 | 2015-12-01 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
| KR20140104475A (ko) * | 2011-12-08 | 2014-08-28 | 프로틴 디자인 랩, 리미티드 | 신규 항생제 제조방법 및 이 방법에 기초한 플랫폼 시스템 |
| CN107106578B (zh) * | 2014-08-12 | 2020-12-25 | 香港大学 | 治疗厄泼斯坦-巴尔病毒相关疾病的双膦酸盐化合物和γδT细胞-介导的疗法 |
| CN104604799B (zh) * | 2015-02-05 | 2017-11-21 | 南华大学 | 一种鉴定eb病毒对淋巴瘤的诱发性的方法 |
| EP3957995A1 (en) * | 2018-11-19 | 2022-02-23 | Bioaster | Methods and reagents for multiplex binding experiments |
| CN111333724B (zh) * | 2018-12-19 | 2022-03-15 | 中国人民解放军军事科学院军事医学研究院 | 一种抗金黄色葡萄球菌肠毒素b的单克隆抗体yg11-1及其应用 |
| CN111848817B (zh) * | 2020-07-28 | 2021-11-09 | 中国农业大学 | 一种兼具抗菌、抗病毒、免疫调节和抗炎活性的多功能杂合肽及其制备方法和应用 |
| CN112125959B (zh) * | 2020-10-10 | 2022-07-29 | 中山大学肿瘤防治中心 | 一种抑制eb病毒的肽和编码该肽的dna及其应用 |
| CN113880914B (zh) * | 2021-04-25 | 2023-11-21 | 内蒙古农业大学 | 一种抗肿瘤多肽及其衍生物 |
| CN114369158B (zh) * | 2021-09-28 | 2024-04-19 | 北京亦科信息菌素研究院有限公司 | 一种抗新冠病毒的信息菌素及其应用 |
| CN113999304B (zh) * | 2021-10-13 | 2023-10-24 | 北京市农林科学院 | 抗肠菌素单克隆抗体mAb4及其在肠菌素检测中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1164612C (zh) | 2001-09-11 | 2004-09-01 | 四川新泰克控股有限责任公司 | 人工组合的抗菌工程多肽及其制备方法 |
| CN1314806C (zh) * | 2005-01-14 | 2007-05-09 | 四川大学 | 小型化抗eb病毒肿瘤多肽及其应用与制备方法 |
| CN1274829C (zh) | 2004-12-10 | 2006-09-13 | 四川大学华西医院 | 抗eb病毒所致肿瘤多肽及其应用与制备方法 |
| WO2007083175A1 (en) * | 2006-01-17 | 2007-07-26 | West China Hospital, Sichuan University | Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith |
| CN101643501B (zh) * | 2008-11-07 | 2012-06-20 | 畿晋庆三联（北京）生物技术有限公司 | 一种新型抗生素及其核苷酸序列、制备方法与应用 |
| CN101633699B (zh) * | 2009-09-02 | 2012-02-15 | 畿晋庆堂国际生物技术有限公司 | 一种含抗体模拟物的新型抗生素及其制备方法与应用 |
-
2009
- 2009-12-17 CN CN2009102428380A patent/CN102101888B/zh not_active Expired - Fee Related
-
2010
- 2010-02-26 BR BR112012017350-2A patent/BR112012017350A2/pt not_active Application Discontinuation
- 2010-02-26 MX MX2012006952A patent/MX2012006952A/es active IP Right Grant
- 2010-02-26 SG SG2012041786A patent/SG181553A1/en unknown
- 2010-02-26 NZ NZ600729A patent/NZ600729A/en not_active IP Right Cessation
- 2010-02-26 UA UAA201208633A patent/UA104933C2/uk unknown
- 2010-02-26 WO PCT/CN2010/070762 patent/WO2011072501A1/zh active Application Filing
- 2010-02-26 AU AU2010333588A patent/AU2010333588B2/en not_active Ceased
- 2010-02-26 JP JP2012543448A patent/JP5683603B2/ja not_active Expired - Fee Related
- 2010-02-26 EA EA201270655A patent/EA030638B1/ru not_active IP Right Cessation
- 2010-02-26 CA CA2784784A patent/CA2784784C/en not_active Expired - Fee Related
- 2010-02-26 AP AP2012006327A patent/AP3535A/xx active
- 2010-02-26 PE PE2012000834A patent/PE20121722A1/es active IP Right Grant
- 2010-02-26 KR KR1020127018638A patent/KR101464842B1/ko active IP Right Grant
- 2010-02-26 DK DK10836940.6T patent/DK2514768T3/en active
- 2010-02-26 US US13/516,605 patent/US8883161B2/en not_active Expired - Fee Related
- 2010-02-26 HU HUE10836940A patent/HUE033298T2/en unknown
- 2010-02-26 EP EP10836940.6A patent/EP2514768B1/en active Active
- 2010-02-26 MA MA35062A patent/MA33921B1/fr unknown
- 2010-02-26 GE GEAP201012791A patent/GEP20156228B/en unknown
- 2010-02-26 ES ES10836940.6T patent/ES2634944T3/es active Active
-
2011
- 2011-12-14 HK HK11113462.9A patent/HK1159123A1/xx not_active IP Right Cessation
-
2012
- 2012-05-24 TN TNP2012000253A patent/TN2012000253A1/en unknown
- 2012-06-11 IL IL220296A patent/IL220296A/en not_active IP Right Cessation
- 2012-06-12 CU CU2012000096A patent/CU20120096A7/es active IP Right Grant
- 2012-06-12 CO CO12098450A patent/CO6541633A2/es unknown
- 2012-06-13 DO DO2012000164A patent/DOP2012000164A/es unknown
- 2012-06-14 CL CL2012001609A patent/CL2012001609A1/es unknown
- 2012-06-15 CR CR20120329A patent/CR20120329A/es unknown
- 2012-07-13 ZA ZA2012/05217A patent/ZA201205217B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2012000164A (es) | Polipeptido de fusion contra tumor inducido por virus eb y mutante de colicina ia | |
| PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| MX2021006239A (es) | Receptores quimericos de antigeno que tienen como diana a cd-19. | |
| MY197846A (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
| CU24058B1 (es) | Antagonistas de pcsk9 | |
| MY193497A (en) | Anti-myostatin antibodies and methods of use | |
| CR20170282A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| PH12014501106B1 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
| BR112012029912A2 (pt) | vácinas de combinação de nanotransportadores sintéticos | |
| MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
| WO2018106776A3 (en) | Anti-tau antibodies and methods of their use | |
| MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
| BR112016016035A2 (pt) | gene resistente à praga antropogênica, anticorpo de cadeia única de idiotípico de toxina anti-cry1ab codificado pelo mesmo e aplicação | |
| MX2021003456A (es) | Spodoptera frugiperda resistente a proteina insecticida vegetativa 3a (vip3a). | |
| WO2018069947A8 (en) | Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine | |
| WO2020022898A3 (en) | Off-the-shelf cancer vaccines | |
| MY197890A (en) | Mutant strains of trichoderma reesei | |
| NZ731491A (en) | Cd83 binding proteins and uses thereof | |
| MX2017005310A (es) | Metodos basados en proximidad para seleccion de parejas para ligadura. | |
| MX2021015766A (es) | Nuevos antigenos y metodos contra el cancer. | |
| MX2015009867A (es) | Mutantes del factor x. | |
| MX2018004322A (es) | Metodo para detectar anticuerpos neutralizantes contra la insulina mana recombinante en suero mano. | |
| BR112018013400A2 (pt) | vacina marcadora de pestivírus | |
| WO2015111013A3 (fr) | Synthetases de la colistine et cluster de genes correspondants | |
| TW201614071A (en) | Aptamer specific to colorectal cancer stem cell and application thereof |